Compare Moderna, Inc. (MRNA) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Match Group Inc — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Match Group Inc trades at $39.02 (market cap $9.10B). The key difference: Moderna, Inc. is far larger — about 2.6× Match Group Inc's market cap, and Match Group Inc pays a 2.05% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | MTCH | |
|---|---|---|
Market Cap | $23.60B | $9.10B |
Sector | Health | Media |
52-Week High | $81.80 | $40.29 |
52-Week Low | $22.36 | $28.90 |
Enterprise Value | $19.70B | $12.05B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
MTCH trades at $38.75, down 1.02% today, near the analyst low target of $38.00. The stock shows a bullish technical signal with strong moving average support, while oscillators remain neutral. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat estimates. Revenue growth is stable at $3.5B annually, with net income margins improving to 17.59% in 2025. Positive news highlights Tinder's turnaround efforts and Hinge's growth, with a dividend scheduled for July 2026.
Outlook is cautiously optimistic with a consensus price target of $41.63, implying ~7% upside. Strengths include high gross margins (73.8%) and consistent cash flow growth. Risks involve high debt ($3.85B) and Tinder's user declines offset by pricing. Analyst sentiment is bullish (53% Buy), but execution on user engagement remains critical for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
